1. Home
  2. IOVA vs ARRY Comparison

IOVA vs ARRY Comparison

Compare IOVA & ARRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IOVA
  • ARRY
  • Stock Information
  • Founded
  • IOVA 2007
  • ARRY 1989
  • Country
  • IOVA United States
  • ARRY United States
  • Employees
  • IOVA N/A
  • ARRY N/A
  • Industry
  • IOVA Biotechnology: Biological Products (No Diagnostic Substances)
  • ARRY Semiconductors
  • Sector
  • IOVA Health Care
  • ARRY Technology
  • Exchange
  • IOVA Nasdaq
  • ARRY Nasdaq
  • Market Cap
  • IOVA 975.1M
  • ARRY 1.1B
  • IPO Year
  • IOVA N/A
  • ARRY 2020
  • Fundamental
  • Price
  • IOVA $2.68
  • ARRY $6.06
  • Analyst Decision
  • IOVA Buy
  • ARRY Buy
  • Analyst Count
  • IOVA 10
  • ARRY 19
  • Target Price
  • IOVA $12.22
  • ARRY $9.31
  • AVG Volume (30 Days)
  • IOVA 26.0M
  • ARRY 6.2M
  • Earning Date
  • IOVA 08-07-2025
  • ARRY 08-07-2025
  • Dividend Yield
  • IOVA N/A
  • ARRY N/A
  • EPS Growth
  • IOVA N/A
  • ARRY N/A
  • EPS
  • IOVA N/A
  • ARRY N/A
  • Revenue
  • IOVA $212,679,000.00
  • ARRY $1,064,767,000.00
  • Revenue This Year
  • IOVA $86.62
  • ARRY $25.90
  • Revenue Next Year
  • IOVA $69.13
  • ARRY $14.14
  • P/E Ratio
  • IOVA N/A
  • ARRY N/A
  • Revenue Growth
  • IOVA 11070.12
  • ARRY N/A
  • 52 Week Low
  • IOVA $1.64
  • ARRY $3.76
  • 52 Week High
  • IOVA $12.51
  • ARRY $10.79
  • Technical
  • Relative Strength Index (RSI)
  • IOVA 53.63
  • ARRY 36.68
  • Support Level
  • IOVA $1.70
  • ARRY $6.60
  • Resistance Level
  • IOVA $4.33
  • ARRY $7.09
  • Average True Range (ATR)
  • IOVA 0.40
  • ARRY 0.39
  • MACD
  • IOVA -0.01
  • ARRY -0.10
  • Stochastic Oscillator
  • IOVA 37.26
  • ARRY 1.16

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

About ARRY Array Technologies Inc.

Array Technologies Inc manufacturer of ground-mounting systems used in solar energy projects. The company's segments include: the Array legacy operating segment (Array Legacy Operations) and the STI Operations operating segment (STI Operations). It derives maximum revenue from the Array legacy operating segment. Its product is an integrated system of steel supports, electric motors, gearboxes and electronic controllers referred to as a single-axis tracker that move solar panels throughout the day to maintain an optimal orientation to the sun, which increases their energy production. Geographically, the company's operations are in the United States, Australia, Spain, Brazil and Rest of the World with the United States deriving the majority of the revenue.

Share on Social Networks: